Despite the best efforts of modern medicine, Huntington’s disease is a condition that still comes with a tragic prognosis.
Pharmaceutical Technology on MSN
FDA halts uniQure’s plans for Huntington’s disease gene therapy
"FDA halts uniQure’s plans for Huntington’s disease gene therapy" was originally created and published by Pharmaceutical ...
Peake relates the story of folk music legend Woody Guthrie, "our greatest advocate," if only by accident. The ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...
On November 3, 2025, uniQure announced a regulatory update regarding its investigational gene therapy for Huntington’s disease, AMT-130, following a pre-Biologics License Application meeting with the ...
uniQure expects to receive final minutes within 30 days of the meeting and plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130.
In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's ...
TAMPA, Fla. (WFLA) — For the first time, scientists have successfully treated someone suffering from Huntington’s disease, a fatal genetic illness with no cure. The Mayo Clinic reports that the ...
UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...
The CEO of the drugmaker Uniqure told investors at a private dinner that the Trump White House “doesn’t like all the drama” inside the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback